Brooks O'Neil

Mathew Blackman

Matthew O'Brien

Michael Kratky

Travis Steed

Felipe Lamar

Frank Takkinen

Jeffrey Johnson

Jonathan Jeff

Kelly Close

Matt O'Brien

Mike Polark

Philip Coover

Stephanie Piazzola

- Beta Bionics reported strong Q3 2025 financial results, with **net sales of $27.3 million**, a **63% year-over-year increase**, and **5,334 new patient starts**, up 68% year-over-year.  **[0001674632_2211205_1]** 
- The company achieved a **gross margin of 55.5%** in Q3 2025, an increase from 53.4% in Q3 2024, driven by increased scale and higher-margin pharmacy revenue.  **[0001674632_2211205_2]** **[0001674632_2211205_3]** 
- Beta Bionics raised its full-year 2025 guidance, now expecting total revenue to be **greater than $96.5 million** (previously $88-$93 million) and gross margin between **54% and 55%** (previously 52%-55%).  **[0001674632_2211205_3]** 
- Adoption through the pharmacy channel continues to accelerate, with **low 30s % of new patient starts** in Q3 2025 utilizing this channel, significantly up from high single-digits in Q3 2024.  **[0001674632_2211205_1]** 
- Progress was noted in the product pipeline, including the Mint patch pump on track for commercialization by the end of **2027**, and the completion of a PK/PD trial for the biohormonal system's glucagon asset.  **[0001674632_2211205_5]**

Beta Bionics Reports Strong Q3 2025 Results and Raises Full-Year Guidance

- Beta Bionics reported **Q3 2025 revenue of $27 million** and a **gross margin of 55%**.  **[0001674632_2208908:6]** **[0001674632_2208908:8]** 
- **New patient starts totaled 5,334** in Q3 2025, with a **low 30s% reimbursed through pharmacy**.  **[0001674632_2208908:6]** **[0001674632_2208908:8]** 
- The company **updated its full-year 2025 guidance**, now projecting **total revenue greater than $96.5 million**, **new patient starts through pharmacy between 27-29%**, and a **gross margin of 54-55%**.  **[0001674632_2208908:7]** 
- Strategic highlights include **effective formulary agreements with all major PBMs** in July 2025 and **iLet Special 510(k) Clearance** for usability improvements in September 2025.  **[0001674632_2208908:6]**

Beta Bionics Reports Q3 2025 Earnings and Updates Full Year Guidance

- Beta Bionics delivered strong Q3 2025 financial performance, with **net sales of $27.3 million**, representing **63% year-over-year growth**, and **5,334 new patient starts**, a **68% year-over-year increase**.  **[0001674632_2211349_1]** **[0001674632_2211349_3]** 
- The company raised its full-year 2025 guidance, projecting total revenue to be **greater than $96.5 million** (up from $88 million-$93 million) and gross margin to be **54%-55%** (up from 52%-55%).  **[0001674632_2211349_3]** 
- Q3 2025 gross margin was **55.5%**, an increase of **212 basis points** compared to Q3 2024.  **[0001674632_2211349_2]** 
- Beta Bionics continues to advance its product pipeline, with the Mint patch pump targeting commercialization by the **end of 2027** and a biohormonal system expected to begin a feasibility trial in Q4 2025.  **[0001674632_2211349_5]** 
- The company is actively addressing an FDA Form 483 related to customer complaint handling and reporting criteria, which will result in an increase in reported complaints as historical data is re-filed, with remediation expected to be completed by the **end of Q2 2026**.  **[0001674632_2211349_6]** **[0001674632_2211349_11]**

- Beta Bionics delivered **$27.3 million in net sales** for Q3 2025, representing **63% year-over-year growth**, driven by **5,334 new patient starts** which increased **68% year-over-year**.  **[0001674632_2209188_1]** 
- The company's **gross margin improved to 55.5%** in Q3 2025, up **212 basis points** compared to Q3 2024 and **167 basis points sequentially** from Q2 2025.  **[0001674632_2209188_2]** 
- Beta Bionics **raised its full-year 2025 revenue guidance to greater than $96.5 million** (from $88-$93 million previously) and **gross margin guidance to 54% to 55%** (from 52%-55% previously).  **[0001674632_2209188_3]** 
- Progress continues on the product pipeline, with the **Mint patch pump on track for commercial launch by the end of 2027** and a **feasibility trial for the biohormonal system expected to initiate in Q4 2025**.  **[0001674632_2209188_5]** 
- The company is actively addressing an **FDA Form 483 related to customer complaint handling**, with remediation efforts expected to be completed by the **end of Q2 2026**.  **[0001674632_2209188_6]** **[0001674632_2209188_12]**

- Beta Bionics reported **net sales of $27.3 million** for the third quarter of 2025, representing a **63% increase** compared to the third quarter of 2024, with a gross margin of **55.5%**.  **[1674632_0001171843-25-006720_exh_991.htm:0]** 
- The company's installed customer base grew **162%** to **29,419 users** as of September 30, 2025, driven by **5,334 new patient starts** in Q3 2025, an increase of **68%** year-over-year.  **[1674632_0001171843-25-006720_exh_991.htm:0]** 
- Beta Bionics raised its full-year 2025 guidance, now expecting total revenue of **greater than $96.5 million** (up from a previous range of $88 million to $93 million) and an estimated gross margin of **54% to 55%**.  **[1674632_0001171843-25-006720_f8k_102825.htm:1]** 
- As of September 30, 2025, the company held **$274.0 million** in cash, cash equivalents, short-term investments, and long-term investments.  **[1674632_0001171843-25-006720_exh_991.htm:0]**

Beta Bionics (BBNX)